Holm, R
What the April 2026 Announcement Changes The FDA's April 15 announcement signals that injectable GHK-Cu will be removed from the Category 2 list, with formal implementation expected in July 2026 when the FDA's peptide advisory panel is scheduled to reconvene and finalize updated guidance
There are two main ways this is done, centrifugation and membrane filtration, and they lead to very different outcomes
Adipose tissue biopsies and SA--gal activity During bariatrics surgery, paired visceral adipose tissue was harvested and using the Senescence Cells Histochemical Staining Kit (Sigma, St Louis), fresh adipose tissue samples were examined for SA--gal activity ( 3 The ratio of cyan pixel intensity to the total number of pixels in the biopsy region, multiplied by 1,000, was used to calculate the SA-gal values, which were then reported as arbitrary units (AU)
PubMed Randomized trialSemaglutide evidence2022 Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight Supports head-to-head context when pages compare older and newer GLP-1 options
Each peptide in the stack operates through a distinct but mechanistically complementary biological pathway BPC-157 driving angiogenesis, fibroblast activation, and extracellular matrix stabilisation, while TB-500 drives cytoskeletal reorganisation, cellular migration, and stem/progenitor cell mobilisation
